Payment overview · 2025
General Payments
$903.06
49 reported records · 12 companies
Healthcare provider profile · identity verified
Roberto L Duran, MD
Allopathic & Osteopathic Physicians|Pain Medicine|Interventional Pain Medicine · JUPITER, FL · NPI 1619915964
Verified facts
What the public records show
CMS Open Payments records show Roberto L Duran, MD received $903.06 in general payments during 2025 across 49 reported records.
PFIZER INC. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Relistor.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $301.97 | 33.4% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $171.47 | 19.0% | 11 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $134.94 | 14.9% | 8 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $68.54 | 7.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $61.81 | 6.8% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $30.78 | 3.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.14 | 2.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.68 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.65 | 2.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.50 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.23 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.35 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $903.06 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $301.97 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $301.97 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $144.38 | 9 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $134.94 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.06 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $61.81 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $6.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| RELISTOR relistor |
2025 | Relistor | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Morphine Sulfate Er | Morphine Sulfate | 569 | 55 |
| Oxycodone Hcl | Oxycodone Hcl | 526 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 382 | 40 |
| Gabapentin | Gabapentin | 275 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 244 | 30 |
| Ibuprofen | Ibuprofen | 193 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 171 | 25 |
| Oxycontin | Oxycodone Hcl | 158 | 13 |
| Xtampza Er | Oxycodone Myristate | 151 | 19 |
| Fentanyl | Fentanyl | 126 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 17 |
| Trazodone Hcl | Trazodone Hcl | 109 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 96 | 13 |
| Methadone Hcl | Methadone Hcl | 95 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 88 | 12 |
| Alprazolam | Alprazolam | 76 | suppressed |
| Meloxicam | Meloxicam | 76 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 13 |
| Baclofen | Baclofen | 64 | 18 |
| Diazepam | Diazepam | 62 | 11 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Lorazepam | Lorazepam | 50 | suppressed |
| Methocarbamol | Methocarbamol | 50 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Relistor | Methylnaltrexone Bromide | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Nucynta Er | Tapentadol Hcl | 36 | suppressed |
| Zonisamide | Zonisamide | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 31 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Buprenorphine | Buprenorphine | 22 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Metaxalone | Metaxalone | 19 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 16 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Symproic | Naldemedine Tosylate | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Belbuca | Buprenorphine Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $903.06 · 49 records | PFIZER INC. | AUSTEDO XR, BOTOX, CREXONT, INGREZZA, JOURNAVX, KISUNLA, Leqembi, NURTEC ODT, PONVORY, QULIPTA, RELISTOR, TYSABRI, UBRELVY, VUMERITY, VYALEV, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Relistor play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error